The Enterprise Value as of November 2024 (TTM) for Inhibikase Therapeutics, Inc. (IKT) is 154.45M

According to Inhibikase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 154.45M. This represents a change of 2.10% compared to the average of 7.02M of the last 4 quarters.

Inhibikase Therapeutics, Inc. (IKT) Historical Enterprise Value (quarterly & annually)

How has IKT Enterprise Value performed in the past?

The mean historical Enterprise Value of Inhibikase Therapeutics, Inc. over the last ten years is 50.98M. The current 154.45M Enterprise Value has changed 30.20% with respect to the historical average. Over the past ten years (40 quarters), IKT's Enterprise Value was at its highest in in the September 2020 quarter at 81.87M. The Enterprise Value was at its lowest in in the June 2022 quarter at -13460170.32.

Inhibikase Therapeutics, Inc. (IKT) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Inhibikase Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Inhibikase Therapeutics, Inc. (IKT) Average Enterprise Value

How has IKT Enterprise Value performed in the past?

The current Enterprise Value of Inhibikase Therapeutics, Inc. (IKT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Inhibikase Therapeutics, Inc. (IKT) Enterprise Value vs. Peers

How is IKT’s Enterprise Value compared to its peers?

Inhibikase Therapeutics, Inc.’s Enterprise Value is less than DiaMedica Therapeutics Inc. (197.21M), greater than Milestone Pharmaceuticals Inc. (139.34M), less than Seres Therapeutics, Inc. (158.02M), greater than Oncolytics Biotech Inc. (84.27M), greater than scPharmaceuticals Inc. (128.65M), greater than aTyr Pharma, Inc. (138.44M), less than Sio Gene Therapies Inc. (0), greater than Kaleido Biosciences, Inc. (-61213000.00), greater than Tempest Therapeutics, Inc. (4.26K), greater than AN2 Therapeutics, Inc. (35.14M), greater than Miromatrix Medical Inc. (6.48M), greater than PMV Pharmaceuticals, Inc. (90.06M), greater than Anebulo Pharmaceuticals, Inc. (47.77M), greater than Nutriband Inc. (36.46M), greater than Quoin Pharmaceuticals, Ltd. (46.88M), greater than Longeveron Inc. (-162664.00), greater than RenovoRx, Inc. (6.86M), greater than Virax Biolabs Group Limited (21.40M), greater than null (5.36M),

Build a custom stock screener for Inhibikase Therapeutics, Inc. (IKT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibikase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibikase Therapeutics, Inc. (IKT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibikase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.